Accelerate Diagnostics (AXDX) Q4 2024 earnings summary

Executive summary

• Q4 2024 net sales declined to $2.8M from $3.0M year-over-year, mainly due to lower consumable sales.

• Full-year 2024 net sales were $11.7M, down from $12.1M in 2023, with a 3% increase in consumable product revenue offset by weak capital sales.

• Q4 net loss was $9.6M ($0.38/share); full-year net loss was $50.0M ($2.15/share).

• Company ended Q4 with $16.3M in cash and equivalents, down from $20.9M at the start of the quarter.

• No plans for regular earnings calls; updates to be provided via SEC filings and investor relations materials.

Financial highlights

• Q4 gross margin fell to 16% from 21% year-over-year due to higher manufacturing costs.

• Full-year gross margin improved to 23% from 21% in 2023.

• Q4 SG&A costs dropped to $4.6M from $5.8M; full-year SG&A was $21.3M, down from $31.2M.

• Q4 R&D costs decreased to $3.8M from $5.6M; full-year R&D was $16.7M, down from $25.4M.

• Adjusted loss from operations (excluding non-cash equity-based comp) was $6.97M in Q4 and $30.93M for the year.

Outlook and guidance

• No explicit forward guidance provided; company will communicate future updates through SEC filings.

• Management highlights ongoing commitment to timely financial disclosures.